Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS
· Delayed Price · Currency is USD
22.74
+0.40 (1.79%)
Jul 10, 2025, 3:24 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
$637,298
Profits / Employee
$99,925
Market Cap
41.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
Mar 31, 2023 | 17,435 | 977 | 5.94% |
Mar 31, 2022 | 16,458 | 425 | 2.65% |
Mar 31, 2021 | 16,033 | 685 | 4.46% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Daiichi Sankyo Company News
- 17 days ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 17 days ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 24 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 4 weeks ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 5 weeks ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 5 weeks ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 5 weeks ago - DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer - Benzinga
- 5 weeks ago - ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial - Benzinga